Literature DB >> 18704962

Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck.

Eric T Shinohara1, Amit Maity, Neha Jha, Robert A Lustig.   

Abstract

BACKGROUND: An estimated 34,000 cases of squamous cell carcinomas of the head and neck (HNSCC) will be diagnosed in 2007 with 7500 estimated deaths. Radiation is commonly used to treat these patients. Preclinical studies have suggested that sirolimus may be an effective radiosensitizer in HNSCC.
METHODS: The present case report describes a patient, status post liver transplant, who was switched to sirolimus for immunosupression. The patient subsequently underwent radiation therapy for a T2N0M0 SCC of the larynx.
RESULTS: The patient had an unusually early response to radiation, with a clinical complete response after 7 fractions of radiation. However, the patients also had toxicity earlier than expected and required a break from radiation after 11 fractions.
CONCLUSIONS: To the authors' knowledge, this is the first observation to suggest that sirolimus is an effective radiosensitizer in patients with HNSCC. We hope that our results will create interest in future clinical studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18704962      PMCID: PMC2737255          DOI: 10.1002/hed.20898

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  30 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

Authors:  Giovanni Stallone; Antonio Schena; Barbara Infante; Salvatore Di Paolo; Antonella Loverre; Giulio Maggio; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

3.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

Authors:  Susan M Chang; Patrick Wen; Timothy Cloughesy; Harry Greenberg; David Schiff; Charles Conrad; Karen Fink; H Ian Robins; Lisa De Angelis; Jeffrey Raizer; Kenneth Hess; Ken Aldape; Kathleen R Lamborn; John Kuhn; Janet Dancey; Michael D Prados
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

4.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Authors:  Stephen Chan; Max E Scheulen; Stephen Johnston; Klaus Mross; Fatima Cardoso; Christian Dittrich; Wolfgang Eiermann; Dagmar Hess; Rudolph Morant; Vladimir Semiglazov; Markus Borner; Marc Salzberg; Valerijus Ostapenko; Hans-Joachim Illiger; Dirk Behringer; Nathalie Bardy-Bouxin; Joseph Boni; Steven Kong; Maria Cincotta; Laurence Moore
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

5.  Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.

Authors:  D L Sorrells; C Meschonat; D Black; B D Li
Journal:  J Surg Res       Date:  1999-07       Impact factor: 2.192

6.  Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.

Authors:  Joseph P Boni; Cathie Leister; Gregor Bender; Virginia Fitzpatrick; Natalie Twine; Jennifer Stover; Andrew Dorner; Fred Immermann; Michael E Burczynski
Journal:  Clin Pharmacol Ther       Date:  2005-01       Impact factor: 6.875

7.  Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

Authors:  D H Gorski; M A Beckett; N T Jaskowiak; D P Calvin; H J Mauceri; R M Salloum; S Seetharam; A Koons; D M Hari; D W Kufe; R R Weichselbaum
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

8.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Authors:  Eric Raymond; Jérôme Alexandre; Sandrine Faivre; Karina Vera; Eric Materman; Joseph Boni; Cathie Leister; Joan Korth-Bradley; Axel Hanauske; Jean-Pierre Armand
Journal:  J Clin Oncol       Date:  2004-05-10       Impact factor: 44.544

9.  Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.

Authors:  Carolina Jiménez-Rivera; Yaron Avitzur; Annie H Fecteau; Nicola Jones; David Grant; Vicky Lee Ng
Journal:  Pediatr Transplant       Date:  2004-06

10.  Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.

Authors:  Ahmedin Jemal; Limin X Clegg; Elizabeth Ward; Lynn A G Ries; Xiaocheng Wu; Patricia M Jamison; Phyllis A Wingo; Holly L Howe; Robert N Anderson; Brenda K Edwards
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

View more
  3 in total

1.  Efficacy and comparative effectiveness of sirolimus as an anticancer drug.

Authors:  Melissa Hu; Oleksandr Ekshyyan; Lilantha Herman Ferdinandez; Xiaohua Rong; Gloria Caldito; Cherie-Ann O Nathan
Journal:  Laryngoscope       Date:  2011-05       Impact factor: 3.325

Review 2.  Cutaneous squamous cell carcinoma in the organ transplant recipient.

Authors:  Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg
Journal:  Oral Oncol       Date:  2020-02-14       Impact factor: 5.337

3.  Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors.

Authors:  Steffi E M van de Ven; Lauranne A A P Derikx; Iris D Nagtegaal; Carla M van Herpen; Robert P Takes; Willem J G Melchers; Marieke Pierik; Tim van den Heuvel; Rob H A Verhoeven; Frank Hoentjen; L H C Nissen
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.